BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 27506669)

  • 1. Pretreatment quality-of-life score is a better discriminator of oesophageal cancer survival than performance status.
    Kidane B; Sulman J; Xu W; Kong Q; Wong R; Knox JJ; Darling GE
    Eur J Cardiothorac Surg; 2017 Jan; 51(1):148-154. PubMed ID: 27506669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline measure of health-related quality of life (Functional Assessment of Cancer Therapy-Esophagus) is associated with overall survival in patients with esophageal cancer.
    Kidane B; Sulman J; Xu W; Kong QQ; Wong R; Knox JJ; Darling GE
    J Thorac Cardiovasc Surg; 2016 Jun; 151(6):1571-80. PubMed ID: 27016795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of neoadjuvant chemoradiation in cT3 oesophageal cancer - A propensity score matched analysis.
    Hölscher AH; Bollschweiler E; Bogoevski D; Schmidt H; Semrau R; Izbicki JR
    Eur J Cancer; 2014 Nov; 50(17):2950-7. PubMed ID: 25307749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors predicting survival in patients with advanced oesophageal cancer: a prospective multicentre evaluation.
    Bergquist H; Johnsson A; Hammerlid E; Wenger U; Lundell L; Ruth M
    Aliment Pharmacol Ther; 2008 Mar; 27(5):385-95. PubMed ID: 18081735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
    Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
    J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of CT-PET after neoadjuvant chemoradiation in the prediction of histological tumour regression, nodal status and survival in oesophageal adenocarcinoma.
    Elliott JA; O'Farrell NJ; King S; Halpenny D; Malik V; Muldoon C; Johnston C; Reynolds JV
    Br J Surg; 2014 Dec; 101(13):1702-11. PubMed ID: 25351460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Clinically Staged Node-Negative Esophageal Adenocarcinoma and Overall Survival Benefit From Neoadjuvant Chemoradiation.
    Gabriel E; Attwood K; Du W; Tuttle R; Alnaji RM; Nurkin S; Malhotra U; Hochwald SN; Kukar M
    JAMA Surg; 2016 Mar; 151(3):234-45. PubMed ID: 26559488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early surgery for failure after chemoradiation in operable thoracic oesophageal cancer. Analysis of the non-randomised patients in FFCD 9102 phase III trial: Chemoradiation followed by surgery versus chemoradiation alone.
    Vincent J; Mariette C; Pezet D; Huet E; Bonnetain F; Bouché O; Conroy T; Roullet B; Seitz JF; Herr JP; Di Fiore F; Jouve JL; Bedenne L;
    Eur J Cancer; 2015 Sep; 51(13):1683-93. PubMed ID: 26163097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can metformin improve 'the tomorrow' of patients treated for oesophageal cancer?
    Van De Voorde L; Janssen L; Larue R; Houben R; Buijsen J; Sosef M; Vanneste B; Schraepen MC; Berbée M; Lambin P
    Eur J Surg Oncol; 2015 Oct; 41(10):1333-9. PubMed ID: 26091848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of neoadjuvant chemoradiotherapy on perioperative outcomes, tumor pathology, and survival in clinical stage II and III esophageal cancer.
    Markar SR; Bodnar A; Rosales J; Song G; Low DE
    Ann Surg Oncol; 2013 Nov; 20(12):3935-41. PubMed ID: 23892525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stage for stage comparison of recurrence patterns after definitive chemoradiotherapy or surgery for oesophageal carcinoma.
    Reid TD; Davies IL; Mason J; Roberts SA; Crosby TD; Lewis WG
    Clin Oncol (R Coll Radiol); 2012 Nov; 24(9):617-24. PubMed ID: 22386923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the Glasgow Prognostic Score in patients receiving chemoradiotherapy for stage III and IV esophageal cancer.
    Kimura J; Kunisaki C; Makino H; Oshima T; Ota M; Oba M; Takagawa R; Kosaka T; Ono HA; Akiyama H; Endo I
    Dis Esophagus; 2016 Nov; 29(8):1071-1080. PubMed ID: 26471766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilization of surgery in trimodality-eligible patients with locally advanced esophageal adenocarcinoma in a nonprotocol setting.
    Murphy CC; Hofstetter WL; Correa AM; Ajani JA; Komaki RU; Swisher SG
    Dis Esophagus; 2013; 26(7):708-15. PubMed ID: 23350713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of locoregional stage esophageal cancer: a single center experience.
    Javle MM; Nwogu CE; Donohue KA; Iyer RV; Brady WE; Khemka SV; Smith JL; Demmy TL; Yang GY; Nava HR
    Dis Esophagus; 2006; 19(2):78-83. PubMed ID: 16643174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of preoperative platelets to lymphocytes ratio (PLR) on survival for oesophageal and junctional carcinoma treated with neoadjuvant chemotherapy: A retrospective monocentric study on 153 patients.
    Messager M; Neofytou K; Chaudry MA; Allum WH
    Eur J Surg Oncol; 2015 Oct; 41(10):1316-23. PubMed ID: 26166786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does Barrett's esophagus respond to chemoradiation therapy for adenocarcinoma of the esophagus?
    Barthel JS; Kucera ST; Lin JL; Hoffe SE; Strosberg JR; Ahmed I; Dilling TJ; Stevens CW
    Gastrointest Endosc; 2010 Feb; 71(2):235-40. PubMed ID: 20003971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutic decisions in patients with operable, non-metastatic oesophageal cancer].
    Fuchs HF; Hölscher AH
    Zentralbl Chir; 2014 Feb; 139(1):32-6. PubMed ID: 24585195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health-related quality of life 10 years after oesophageal cancer surgery.
    Schandl A; Lagergren J; Johar A; Lagergren P
    Eur J Cancer; 2016 Dec; 69():43-50. PubMed ID: 27816831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes.
    Shao MS; Wong AT; Schwartz D; Weiner JP; Schreiber D
    Ann Thorac Surg; 2016 Jun; 101(6):2148-54. PubMed ID: 27016842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
    Liao Z; Zhang Z; Jin J; Ajani JA; Swisher SG; Stevens CW; Ho L; Smythe R; Vaporciyan AA; Putnam JB; Walsh GL; Roth JA; Yao JC; Allen PK; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1484-93. PubMed ID: 15590179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.